Yanagawa E, Toge T, Yamaguchi Y, Kuninobu H, Kuroi K, Kegoya Y, Baba N, Takayama T, Sato Y
Department of Surgery, Hiroshima University, Japan.
Jpn J Surg. 1991 May;21(3):297-303. doi: 10.1007/BF02470950.
The effects of OK432, a streptococcal preparation, administered either orally (PO-OK432) or intratumorally (IT-OK432) on the immuno-reactivities of regional lymph nodes were investigated in gastric cancer patients. Although native lymph node lymphocytes (LNL) from untreated patients did not show any cytotoxicities against K562 and Raji cells, enhanced activities were found in LNL from patients administered OK432. Augmenting effects on the cytotoxicities of LNL by in vitro additional OK432, interleukin 2 or gamma-interferon were remarkable in the patients given IT-OK432. Moreover, the cytotoxicities of peripheral blood lymphocytes were augmented in vitro more strongly in patients given IT-OK432 than in those given PO-OK432. Flow cytometric analysis of LNL revealed a decrease in CD4+ cells by PO-OK432 and an increase in CD8+ cells by IT-OK432. An increase in CD4+2H4+ cells and a decrease in CD4+2H4- cells were observed in the patients given OK432, though CD8+CD11+ cells decreased by PO-OK432 while CD8+CD11+ cells increased by IT-OK432. Thus, it is suggested that LNL reactive to OK432 immunotherapy may differ between PO- and IT-OK432, and that the immunoreactivities of local lymph nodes and systemical immuno-reactivities may be highly potentiated by IT-OK432 rather than PO-OK432.
在胃癌患者中,研究了口服(PO-OK432)或瘤内注射(IT-OK432)链球菌制剂OK432对区域淋巴结免疫反应性的影响。尽管未经治疗患者的天然淋巴结淋巴细胞(LNL)对K562和Raji细胞未显示出任何细胞毒性,但在接受OK432治疗的患者的LNL中发现活性增强。在接受IT-OK432治疗的患者中,体外额外添加OK432、白细胞介素2或γ干扰素对LNL细胞毒性的增强作用显著。此外,接受IT-OK432治疗的患者外周血淋巴细胞的体外细胞毒性增强程度比接受PO-OK432治疗的患者更强。LNL的流式细胞术分析显示,PO-OK432使CD4+细胞减少,IT-OK432使CD8+细胞增加。接受OK432治疗的患者中观察到CD4+2H4+细胞增加,CD4+2H4-细胞减少,尽管PO-OK432使CD8+CD11+细胞减少,而IT-OK432使CD8+CD11+细胞增加。因此,提示对OK432免疫治疗有反应的LNL在PO-OK432和IT-OK432之间可能存在差异,并且IT-OK432比PO-OK432更能显著增强局部淋巴结的免疫反应性和全身免疫反应性。